Case Report

Chorea as the First and Only Manifestation of Systemic Lupus Erythematous

Abdul Razzakh Poil, 1 Fahmi Yousef Khan, 2 Abdo Lutf, 1 and Mohammed Hammoudeh 1

1 Rheumatology Division, Department of Medicine, Hamad General Hospital, Doha, Qatar
2 Department of Medicine, Hamad General Hospital, Doha, Qatar

Correspondence should be addressed to Abdul Razzakh Poil, drrazzakh@gmail.com

Received 19 June 2012; Accepted 23 August 2012

Academic Editors: G. S. Alarcon, A. Chalmers, C. Orellana, and G. J. Tsay

Copyright © 2012 Abdul Razzakh Poil et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

We report a case of right-sided hemichorea associated with systemic lupus erythematous (SLE) in a female patient who presented with involuntary movements of hand and foot, without any other manifestation of SLE. Further workup showed positive tests for antinuclear antibody, anti-Smith antibody, anti-dsDNA, and antiphospholipid antibody (aPL). The patient was started on aspirin and hydroxychloroquine and her chorea resolved after three weeks of followup. This is one of the few reported cases of SLE where chorea is presented as the first and only manifestation of SLE.

1. Introduction

Central nervous system (CNS) lupus is a serious but potentially treatable illness, which still presents a very difficult diagnostic challenge. The frequency of neuropsychiatric manifestations in SLE varies widely, depending on the type of manifestations and the method used for evaluation [1]. However, neurologic and psychiatric symptoms are reported to occur in 14 to 80 percent of patients either prior to the diagnosis of SLE, or during the course of their illness [2]. Chorea is a relatively uncommon manifestation of SLE; however, chorea as the first and sole manifestation of SLE is extremely rare [3]. In this paper, we present a young woman who presented with hemichorea as a first and sole manifestation of SLE.

2. Case Report

A 27-year-old female presented to emergency room with involuntary movements of her right arm and leg. These movements had started 4 weeks earlier and gradually became worse, involving the right side of the body; she had difficulty in holding things with her right hand and difficulty in walking. There was no history of rash, photosensitivity, hair loss, oral ulcer, Raynaud’s phenomenon, dryness of mouth or eyes, oral contraceptive intake, weight loss, headache, loss of consciousness, or seizure. She had no family history of rheumatic or neurological diseases and her past medical history was unremarkable. She denied smoking and alcohol consumption. The patient was multigravida, she had two children; both pregnancies were uneventful.

Physical examination revealed choreic movements of her right hand and foot. They were jerky, purposeless, intermittent, and irregular movements. Examination of other systems was unremarkable.

Initial investigations showed a normal complete blood count, blood chemistry, and liver function tests. Her coagulation profile was normal except for prolonged activated partial thromboplastin time (APTT) of 68.8 seconds (25 sec to 36.5 second). Antinuclear antibody (ANA) was 1:1280, and Anti-dsDNA was 70.5 IU (<25 IU) and anti-Smith antibody was also positive. Her C3 was low and C4 complement was normal. Lupus anticoagulant was positive and anticardiolipin IgG was borderline positive-18.5 GPL (<15 GPL), but anticardiolipin IgM antibody and anti-beta 2 glycoprotein-1 were negative. Antistreptolysin O (ASO) titre was 157 IU/mL (<200 IU/mL) and thyroid function tests were normal. Magnetic resonance imaging (MRI) of brain showed tiny foci
of high-intensity signal in FLAIR and T2-weighted image in bilateral basal ganglia and occipital periventricular white matter (Figures 1(a) and 1(b)). Magnetic resonance angiography (MRA) showed normal cerebral arterial caliber with no area of stenosis or occlusion, or aneurysmal dilatation.

In view of these findings, the patient was diagnosed with systemic lupus erythematosus (SLE) and was treated with aspirin and hydroxychloroquine. After three weeks of followup, her chorea resolved completely. She was followed in rheumatology for the past 6 months without any recurrence.

3. Discussion

The incidence of chorea in SLE varies in different studies. It ranges from 1% to 8% [4, 5], and it is strongly associated with antiphospholipid (aPL) antibodies, especially anticardiolipin and lupus anticoagulant [6]. Although chorea usually occurs during the course of SLE, it may also be, the presenting feature of the illness, sometimes preceding other symptoms by several years [7], or it might be the sole manifestation of SLE as in our case.

There are many explanations regarding pathophysiology of chorea in SLE, one such explanation is that it is immune-mediated mechanism secondary to aPL antibodies mainly anticardiolipin IgG as in our case [6, 8].

Another potential pathogenic mechanism for lupus chorea is ischemia affecting the basal ganglia or the tracts connecting the basal ganglia, thalamus, and cerebral cortex. Some of these ischemic events might be related to thrombosis mediated by IgG anticardiolipin antibodies as in our patient (see MRI picture) [8, 9].

The differential diagnosis of chorea includes cerebrovascular accidents, drug intoxication, hyperthyroidism, Huntington’s disease, Sydenham’s chorea, and collagen vascular diseases like SLE.

In our patient, cerebrovascular accident was excluded as MRI was unremarkable. Regarding the drug history, our patient denied receiving any triggering drugs prior to this episode. Huntington’s chorea was excluded from the history since there was no personal or family history of abnormal movements. Hyperthyroidism was excluded by normal thyroid function test, whereas the absence of history of rheumatic fever and antecedent streptococcal infections made the diagnosis of rheumatic fever (Sydenham’s chorea) unlikely.

Our patient does not meet the ACR criteria for SLE, but positive anti-Smith and anti-dsDNA antibodies make SLE the most likely diagnosis, since anti-Smith is exclusively found in SLE if anti-dsDNA is also present [10, 11].

One of the commonest MRI findings of neuropsychiatric SLE is periventricular white matter hyperintensities in T2 and FLAIR images, as in our case (see MRI picture) [12].

Most of the patients with chorea secondary to SLE improve without any treatment and there is no role for anticoagulation in the treatment of chorea in the absence of a thromboembolic event. Alternatively, prednisone, dopamine antagonists, and antiplatelet agents appear to be effective to treat chorea in SLE patients with antiphospholipid antibodies [8, 13]. Considering her mild chorea, we did not start her on immunosuppressive or dopamine antagonists.

In conclusion, chorea is a well-recognized but rare manifestation of SLE; it could be the initial and the sole presentation of SLE and the diagnosis should be pursued when other causes of chorea are excluded.

Conflict of Interests

The authors declare that they have no conflict of interests.

Acknowledgment

We acknowledge Abdul Razzaq Poil and Abdo Lutf are Specialist at rheumatology division, while Mohammed Hammoudeh is the head of the same division.
References

[1] M. Postal, L. T. Costallat, and S. Appenzeller, “Neuropsychiatric manifestations in systemic lupus erythematosus: epidemiology, pathophysiology and management,” CNS Drugs, vol. 25, no. 9, pp. 721–736, 2011.

[2] M. Vadacca, F. Buzzulini, A. Rigon et al., “Neuropsychiatric lupus erythematosus,” Reumatismo, vol. 58, no. 3, pp. 177–186, 2006.

[3] A. M. Walker, D. M. Kaufman, C. R. Pfeffer, and G. E. Solomon, Child and Adolescent Neurology for Psychiatrists, Lippincott Williams & Wilkins, 2008.

[4] M. L. Ishimori, B. D. Pressman, D. J. Wallace, and M. H. Weisman, “Posterior reversible encephalopathy syndrome: another manifestation of CNS SLE?” Lupus, vol. 16, no. 6, pp. 436–443, 2007.

[5] A. I. Quintero-Del-Rio and V. Miller, “Neurologic symptoms in children with systemic lupus erythematosus,” Journal of Child Neurology, vol. 15, no. 12, pp. 803–807, 2000.

[6] J. F. Baizabal-Carvallo, M. Alonso-Juarez, and M. Koslowski, “Chorea in systemic lupus erythematosus,” Journal of Clinical Rheumatology, vol. 17, no. 2, pp. 69–72, 2011.

[7] M. A. Khamashta, A. Gil, B. Anciones et al., “Chorea in systemic lupus erythematosus: association with antiphospholipid antibodies,” Annals of the Rheumatic Diseases, vol. 47, no. 8, pp. 681–683, 1988.

[8] N. M. Orzechowski, A. P. Wolanskyj, J. E. Ahlskog, N. Kumar, and K. G. Moder, “Antiphospholipid antibody-associated chorea,” Journal of Rheumatology, vol. 35, no. 11, pp. 2165–2170, 2008.

[9] R. Cervera, R. A. Asherson, J. Font et al., “Chorea in the antiphospholipid syndrome: clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature,” Medicine, vol. 76, no. 3, pp. 203–212, 1997.

[10] W. Egner, “The use of laboratory tests in the diagnosis of SLE,” Journal of Clinical Pathology, vol. 53, no. 6, pp. 424–432, 2000.

[11] P. Migliorini, C. Baldini, V. Rocchi, and S. Bombardieri, “Anti-Sm and anti-RNP antibodies,” Autoimmunity, vol. 38, no. 1, pp. 47–54, 2005.

[12] J. van der Grond, T. W. J. Huizinga, B. J. Emmer et al., “Neuropsychiatric systemic lupus erythematosus: lessons learned from magnetic resonance imaging,” Arthritis & Rheumatism, vol. 63, no. 3, pp. 722–732, 2011.

[13] G. K. Bertias, J. P. A. Ioannidis, M. Aringer et al., “EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs,” Annals of the Rheumatic Diseases, vol. 69, no. 12, pp. 2074–2082, 2010.